Your session is about to expire
← Back to Search
Remote Exercise Program for Myotonic Dystrophy
N/A
Waitlist Available
Led By Elise Duchesne
Research Sponsored by Université du Québec à Chicoutimi
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 12
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new web tool that could help people with myotonic dystrophy type 1 (DM1) stay physically healthy, which is especially important during the COVID-19 pandemic.
Who is the study for?
This trial is for people aged 18-60 with confirmed Type 1 Myotonic Dystrophy (DM1) who can exercise and consent voluntarily. It's not for those who already train more than three times a week or over 150 minutes weekly, don't speak French or English, or cannot exercise even while seated.
What is being tested?
The study tests the PACE tool, a web-based program offering physical activity routines tailored to DM1 patients' needs. Participants will use it daily for 12 weeks to see if it improves their physical and cognitive health without risking COVID-19 exposure.
What are the potential side effects?
Since this intervention involves remote physical activities adapted to participants' abilities, side effects may include typical exercise-related issues such as muscle soreness or fatigue but should be minimal due to the personalized nature of the programs.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ week 12
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 12
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in Functional capacity from baseline to week 12
Change in the Level of physical activity from baseline to week 12
Feasability/acceptability of the program and Satisfaction
Secondary study objectives
Changes in the Marin apathy scale from baseline to week 12
Changes in the score of the Fatigue and Daytime Sleepiness Scale from baseline to week 12
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Remote activity programExperimental Treatment1 Intervention
Activity program based on objective evaluation. Possibility of 35 different programs primarily targeting impairments (lower limb, upper limb or balanced)
Find a Location
Who is running the clinical trial?
Université du Québec à ChicoutimiLead Sponsor
5 Previous Clinical Trials
245 Total Patients Enrolled
Elise DuchesnePrincipal InvestigatorUniversité du Québec à Chicoutimi
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You already exercise for more than 3 times a week or more than 150 minutes a week.You cannot do any physical activity, even while sitting.You need to have a confirmed diagnosis of DM1 through genetic testing, regardless of your age when the symptoms started.You are between 18 and 60 years old.You are capable of exercising.
Research Study Groups:
This trial has the following groups:- Group 1: Remote activity program
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.